Euro Ewing 2012
The American Ewing sarcoma regimen beat the European one in a head-to-head trial, unifying practice.
3-year EFS 67% vs 61% favouring VDC/IE (HR 0.71); OS HR 0.62; less toxicity and shorter duration. VDC/IE is now the international standard (JCO 2023).
- 67 vs 61 out of 100 free of a major event at 3 years with VDC/IE compared with VIDE; 6 more per 100.
- Roughly one extra person helped for every 17 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 29 percent lower chance of the event at any given time (hazard ratio 0.71, likely range 0.55 to 0.92).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Newly diagnosed Ewing sarcoma: VDC/IE (US-style) vs VIDE/VAI (European) induction/consolidation. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- TrialINT-0091 (Ewing sarcoma)
Shares Ifosfamide, Doxorubicin, Sarcomas (soft tissue, bone, GIST).
- TrialANNOUNCE
- TrialInterfant-06
Shares SIOP Europe – European Society for Paediatric Oncology, Rare and paediatric cancers without markets.
- TrialSIOPEN HR-NBL1
Shares SIOP Europe – European Society for Paediatric Oncology, Rare and paediatric cancers without markets.
- TrialISG-STS 1001
- PairingCaution: cumulative anthracycline dose and the heart
- CompanySpringWorks Therapeutics (Merck KGaA)
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaMandatory national virtual tumour boards for rare and complex cancers
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).